Alveolar capillary dysplasia
Other Names for this Disease
- Alveolar capillary dysplasia with misalignment of pulmonary veins
- Alveolar capillary dysplasia with pulmonary venous misalignment
- Congenital alveolar capillary dysplasia
- Familial persistent pulmonary hypertension of the newborn
- Pulmonary hypertension, familial persistent of the newborn
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.
Medical ProductsThe medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.
|Generic Name||Nitric oxide|
(INO Therapeutics, Inc.)
The FDA has approved this product to be used in this manner.
|In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it i|
|More Information about this product||Drug Information Portal|